Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by askretkaon Jul 18, 2023 10:13am
176 Views
Post# 35545824

Been getting a few requests on why I think CRC and pelareore

Been getting a few requests on why I think CRC and pelareoreWill Pelareorep get a P3 in Colorectal cancer. 

Here's a few of my links to support that theory. 

 
"Oncolytic reovirus (pelareorep) is a non-enveloped dsRNA virus that selectively lyses KRAS-mutated colorectal tumor cells. KRAS mutations are prevalent in 40-45% of colorectal cancer (CRC) patients, and treatment options are limited."  JULY 2022.
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334725/
 
 
 
Immune characterization of metastatic colorectal cancer patients post reovirus.  2020.
 
 administrationhttps://pubmed.ncbi.nlm.nih.gov/32552875/
 
 
Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.  2014.
 
https://pubmed.ncbi.nlm.nih.gov/24798549/
 
 
Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer 2020.
 
 
https://pubmed.ncbi.nlm.nih.gov/32156785/
 
 
Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer. 2021.
 
https://aacrjournals.org/clincancerres/article/27/3/865/83394/Oncolytic-Reovirus-pelareorep-Induces-Autophagy-in

April 2023 Colorectal and Stem cells.

https://www.sciencedirect.com/science/article/pii/S0753332223001610

Reovirus Colorectal and Stem cells 

https://www.sciencedirect.com/science/article/abs/pii/S0006295221002574






 
<< Previous
Bullboard Posts
Next >>